Drug Discovery: A Historical Perspective
Abstract
Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES AND NOTES
1
J. Drews, in Quest of Tomorrow's Medicines (Springer- Verlag, New York, 1999), pp. 51–68.
2
F. J. Moore, A History of Chemistry (McGraw-Hill, New York, 1918), pp. 212–220.
3
A. M. Roberts, Serendipity (Wiley, New York, 1989), pp. 66–74.
4
P. Ehrlich, in Gesammelte Arbeiten, F. Himmelweit, Ed. (Springer-Verlag, Berlin, 1957).
5
Sertürner F. W., Gilbert's Annalen d. Physik 25, 56 (1817).
6
W. Sneader, Drug Discovery (Wiley, New York, 1985).
7
E. Farber, The Evolution of Chemistry; a History of Its Ideas, Methods, and Materials, L. Fiebiger, Ed. (Ronald Press, New York, 1952), pp. 173–188.
8
Koch-Weser J., Schechter P. J., Life Sci. 22, 1361 (1978).
9
H. C. Peyer, Roche-Geschichte einer Unternehmung, 1896–1996 (Roche, Basel, 1996).
10
Chain E., et al., Lancet i, 226 (1940).
11
Fleming A., Br. J. Exp. Pathol. 10, 226 (1940).
12
Taylor H. R., Int. Ophthalmol. 2, 83 (1987).
13
Alberts A. W., Am. J. Cardiol. 15, 10J (1988).
14
D. J. G. White, Ed., Proceedings of an International Conference on Cyclosporin A (Elsevier, Amsterdam, 1982), pp. 5–19.
15
Tanaka H., et al., Yakugaku Zasshi 8, 542 (1997).
16
Meldrum N. U., Roughton F. J., J. Physiol. 80, 113 (1933).
17
Schwartz W. B., N. Engl. J. Med. 240, 173 (1949).
18
R. A. Maxwell and S. B. Eckhardt, Drug Discovery: A Casebook and Analysis (Humana, Clifton, NJ, 1990).
19
Langley J. N., J. Physiol. (London) 33, 374 (1905).
20
Ahlquist R. P., Am. J. Physiol. 1, 100 (1948).
21
J. W. Black, in Drug Responses in Man (CIBA Foundation Symposium, Basel, Switzerland, 1967), pp. 111–117.
22
Z. Bacq, in Discoveries in Pharmacology, M. J. Parham and J. Braunfels, Eds. (Elsevier, Amsterdam, 1983), vol.1, pp. 49–101.
23
Hunkeler W., et al., Nature 290, 514 (1981).
24
Buske C., et al., Eur. J. Cancer 4, 549 (1999).
25
J. Drews, in Human Disease—from Genetic Causes to Biochemical Effects, J. Drews and St. Ryser, Eds. (Blackwell, Berlin, 1997), pp. 5–9.
26
J. Drews and St. Ryser, Classic Drug Targets. Special Pullout [Nature Biotechnol. 15 (1997)].
27
Zipkin I., Michael A., BioCentury 7, 1 (1999).
28
Cragg M. S., et al., Curr. Opin. Immunol. 5, 541 (1999).
29
Drews J., Drug Discovery Today 3, 491 (1998).
30
Köhler G., Milstein C., Nature 256, 495 (1975).
31
Winter G., Harris W. J., Trends Pharmacol. Sci. 14, 139 (1993).
32
Queen C., et al., Proc. Natl. Acad. Sci U.S.A. 86, 10029 (1989).
33
Bruggemann M., Neuberger M. S., Immunol. Today 8, 391 (1996).
34
Huse W. D., et al., Science 246, 1275 (1989).
35
Hoogenboom H. R., et al., Immunotechnology 4, 1 (1998).
36
Rodi D. J., Makowski L., Curr. Opin. Biotechnol. 10, 87 (1999).
37
S. Wright, Evolution and the Genetics of Populations: Genetic and Biometric Foundations (Univ. of Chicago Press, Chicago, IL, 1984).
38
P. J. Guillauseau, D. Tielmans, M. Virally-Monod, M. Assayag, Diabetes Metab. 23 (Suppl. 2), 14 (1997).
39
Shimkets R. A., Lifton R. P., Curr. Opin. Nephrol. Hypertens. 2, 162 (1996).
40
J. Drews and St. Ryser, Drug Discovery Today2, 365 (1997).
41
M. Sills, personal communication.
42
J. Drews and St. Ryser, Drug Inf. J. 30, 97 (1996).
43
Drews J., Drug Discovery Today 3, 491 (1998).
44
Lahana R., Drug Discovery Today 4, 447 (1999).
45
Mayer T. U., et al., Science 286, 971 (1999).
46
Foster B. A., et al., Science 286, 2507 (1999).
47
Aramburu J., et al., Science 285, 2129 (1999).
48
Haffner S. M., Mykkanen L. A., Gonzalez C. C., Stern M. P., Int. J. Obes. Rel. Metab. Disord. 7, 695 (1998).
49
Hussain M. M., Strickland D. K., Bakillah A., Annu. Rev. Nutr. 19, 141 (1999).
50
Sakiniene E., Heyman B., Tarkowski A., Scand. J. Immunol. 3, 250 (1999).
51
Chouchane L., et al., Int. Arch. Allergy Immunol. 120, 50 (1999).
52
St. Ligget, in preparation.
53
Kuivenhoven J. A., et al., N. Engl. J. Med. 338, 86 (1998).
54
St.
Dixon L., Villar H. O., J. Chem. Inf. Comp. Sci. 38, 1192 (1998).
55
Kauvar L. M., et al., Chem. Biol. 2, 107 (1995).
56
St.
Burley K., et al., Nature Genet. 23, 151 (1999).
57
Lindley P. F., Acta Crystallogr. D. 55, 1654 (1999).
58
Brenner S. E., Chothia C., Hubbard T., Curr. Opin. Struct. Biol. 7, 369 (1997).
59
Wells J. A., et al., Recent Prog. Hormone Res. 48, 253 (1993).
60
Stigers K. D., Soth M. J., Nowick J. S., Curr. Opin. Chem. Biol. 6, 714 (1999).
61
Clackson T., Wells J. A., Science 267, 383 (1995).
62
L. S. Goodman et al., Eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics (McGraw-Hill, New York, ed. 9, 1996).
63
I am indebted to J. Curtis for doing the illustrations.
64
{newshr}Review
(0)eLetters
eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter.
Log In to Submit a ResponseNo eLetters have been published for this article yet.
Information & Authors
Information
Published In
Science
Volume 287 | Issue 5460
17 March 2000
17 March 2000
Submission history
Published in print: 17 March 2000
Authors
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Cite as
- Jürgen Drews
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Toward Unified AI Drug Discovery with Multimodal Knowledge, Health Data Science, 4, (2024)./doi/10.34133/hds.0113
- High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor, Science, 318, 5854, (1258-1265), (2021)./doi/10.1126/science.1150577
- LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake, Science, 317, 5843, (1390-1393), (2021)./doi/10.1126/science.1147614
- NIH Molecular Libraries Initiative, Science, 306, 5699, (1138-1139), (2021)./doi/10.1126/science.1105511
- Tetrahydrobiopterin Biosynthesis as an Off-Target of Sulfa Drugs, Science, 340, 6135, (987-991), (2013)./doi/10.1126/science.1232972
Loading...
View Options
Check Access
Log in to view the full text
AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your AAAS ID
- Purchase Access to Other Journals in the Science Family
- Account Help
Log in via OpenAthens.
Log in via Shibboleth.
More options
Purchase digital access to this article
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.